PLEASE NOTE: *This study has been imported from ClinicalTrials.gov without additional data checks.*

Trial Description

Title

A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Alisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC).

Trial Acronym

[---]*

URL of the trial

[---]*

Brief Summary in Lay Language

**This is a two-arm, randomized, double-blind, placebo-controlled, multicenter, phase 2 study
designed to evaluate the efficacy and safety of alisertib, an Aurora A kinase inhibitor, in
combination with paclitaxel compared with placebo + paclitaxel in patients with SCLC who
have relapsed or did not respond to first line standard therapy.**

Brief Summary in Scientific Language

**Randomization will be stratified by the type of relapse after primary treatment (sensitive
or resistant/refractory disease) and presence of brain metastases.**

Organizational Data

- DRKS-ID: **DRKS00007849**
- Date of Registration in DRKS: **2015/05/18**
- Date of Registration in Partner Registry or other Primary Registry: **2013/12/04**
- Investigator Sponsored/Initiated Trial (IST/IIT): **no**
- Ethics Approval/Approval of the Ethics Committee: **[---]***
- (leading) Ethics Committee Nr.: **[---]***

Secondary IDs

- Universal Trial Number (UTN): **U1111-1154-9805**
- EudraCT-No.
  (for studies acc. to Drug Law): **2013-003713-18**
- Primary Registry-ID: **NCT02038647 (ClinicalTrials.gov)**
- Sponsor-ID: **C14018 (Millennium Pharmaceuticals, Inc.)**
- Other Secondary-ID: **2013-003713-18**
- Other Secondary-ID: **U1111-1154-9805**

Health condition or Problem studied

- Free text: **Small Cell Lung Cancer (SCLC)**
- ICD10: **C34 - Malignant neoplasm of bronchus and lung**

Interventions/Observational Groups

- Arm 1: **Drug: Alisertib (MLN8237)**
- Arm 2: **Drug: Placebo**
- Arm 3: **Drug: Paclitaxel 60 mg/m2**
- Arm 4: **Drug: Paclitaxel 80 mg/m2**

Characteristics

- Study Type: **Interventional**
- Study Type Non-Interventional: **[---]***
- Allocation: **Single arm study**
- Blinding: **[---]***
- Who is blinded: **patient/subject, caregiver, investigator/therapist, assessor**
- Control: **Uncontrolled/Single arm**
- Purpose: **Treatment**
- Assignment: **Single (group)**
- Phase: **II**
- Off-label use (Zulassungsüberschreitende Anwendung eines Arzneimittels): **[---]***

Primary Outcome

- Progression-free survival (PFS); time frame: Up to 22 months

Secondary Outcome

- Overall survival (OS); time frame: Up to 22 months
- Overall response rate (ORR), including complete response rate (CRR); time frame: Duration of study until disease progression up to 22 months.
- Safety and health related quality of life (HRQOL); time frame: From screening period to the specified number of PFS events up to 22 months.
- Biomarker correlative studies including circulating tumor cells and circulating DNA assessments; time frame: Twice in cycle 1 in a 28-day cycle
- Disease control rate (DCR); time frame: From screening period to 30 days after last dose of study drug up to 22 months.
- Duration of response (DOR); time frame: From screening period to 30 days after last dose of study drug up to 22 months.

Countries of recruitment

- US **United States**
- BE **Belgium**
- CA **Canada**
- CZ **Czech Republic**
- FR **France**
- DE **Germany**
- HU **Hungary**
- IT **Italy**
- PL **Poland**
- ES **Spain**

Locations of Recruitment

- **Freiburg**
- **Frankfurt**
- **Essen**
- **Recklinghausen**
- **Coswig**
- **Luebeck**
- **Berlin**

Recruitment

- Planned/Actual: **[---]***
- (Anticipated or Actual) Date of First Enrollment: **2014/02/27**
- Target Sample Size: **166**
- Monocenter/Multicenter trial: **Multicenter trial**
- National/International: **International**

Inclusion Criteria

- Gender: **Both, male and female**
- Minimum Age: **18 Years**
- Maximum Age: **no maximum age**

Additional Inclusion Criteria

Inclusion Criteria

Each patient must meet all the following inclusion criteria to be enrolled in the study:

1. Male or female patients ≥ 18 years old

2. Have a pathologically (histology or cytology) confirmed diagnosis of SCLC

3. Have received and progressed after a platinum-based standard chemotherapy regimen for first line treatment of SCLC, either limited stage (LS) or extensive stage (ES).

4. Have measurable disease within ≤ 2 weeks before randomization. Clear radiographic evidence of disease progression after initial therapy should have been documented.

5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1 (PS 0-1).

6. Patients with treated brain metastases (surgery, whole or stereotactic brain radiation) are allowed provided the lesions have been stable for at least 2 weeks and the patient is off steroids or is on a stable dose of steroids. Patients should be without neurologic dysfunction that would confound the evaluation of neurological and/or other AEs.

Exclusion criteria

Exclusion Criteria

Patients meeting any of the following exclusion criteria are not to be randomized to treatment:

1. Any prior therapy for second-line treatment of SCLC.

2. Patients who relapsed ≥ 180 days after their response to first-line treatment.

3. Prior treatment with an Aurora A specific-targeted or pan-Aurora-targeted agent, including alisertib, or any other investigational agent.

4. Prior treatment with paclitaxel or any other taxane agent.

5. Known hypersensitivity to Cremophor® EL, paclitaxel, or its components.

6. Any comorbid condition or unresolved toxicity that would preclude administration of alisertib or weekly paclitaxel.

7. Prior history of ≥ Grade 2 neurotoxicity that is not resolved to ≤ Grade 1

8. Patients with symptomatic and/or progressive brain metastases or with carcinomatous meningitis.

9. Treatment with clinically significant enzyme inducers within 14 days prior to the first dose of alisertib and during study conduct. Major prohibited enzyme inducers include: phenytoin, carbamazepine, phenobarbital, rifampin, rifabutin, rifapentine, and St. John's wort.

10. Inability to swallow alisertib or other orally administered medications.

11. Requirement for administration of proton pump inhibitor (PPI), H2 antagonist, or pancreatic enzymes.

12. Diagnosed with or treated for another malignancy within 2 years before the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease.

13. Other severe acute or chronic medical or psychiatric condition(s) per protocol.

14. History of myocardial infarction, unstable symptomatic ischemic heart disease, uncontrolled hypertension despite appropriate medical therapy, any

ongoing cardiac arrhythmias of Grade > 2, thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (eg, pericardial effusion or restrictive cardiomyopathy) within 6 months before receiving the first dose of study drug.

15. Known history of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C.

16. Surgery within 3 weeks (or 2 weeks for a minor surgery) before study enrollment and not fully recovered to baseline or to a stable clinical status.

17. Patients who are pregnant, lactating, or do not agree to use effective methods of contraception during the study treatment period through 6 months after the last dose of study drug per protocol.

Addresses

- **Primary Sponsor**

  Millennium Pharmaceuticals, Inc.

  Telephone: **[---]***
  Fax: **[---]***
  E-mail: **[---]***
  URL: **[---]***

- **Contact for Scientific Queries**

  Millennium Pharmaceuticals, Inc.
  Medical Monitor

  Telephone: **[---]***
  Fax: **[---]***
  E-mail: **[---]***
  URL: **[---]***

- **Contact for Public Queries**

  For an updated listing of recruitment sites contact: Millennium Medical and Drug Information Center

Contact for Public Queries

For an updated listing of recruitment sites contact: Millennium Medical and Drug Information Center

Telephone: **1-877-674-3784**
Fax: **[---]***
E-mail: **medical at mlnm.com**
URL: **[---]***

Sources of Monetary or Material Support

- **[---]***

Bitte wenden Sie sich an den Sponsor / Please refer to primary sponsor

Telephone: **[---]***
Fax: **[---]***
E-mail: **[---]***
URL: **[---]***

Status

- Recruitment Status: **Recruiting ongoing**
- Study Closing (LPLV): **[---]***

Trial Publications, Results and other documents

The parameters in ClinicalTrials.gov and DRKS are not identical. Therefore the data import from ClinicalTrials.gov required adjustments. For full details please see the DRKS FAQs.
- Translation on version: 4
- Last processed date by ClinicalTrials.gov: 2015/02/24

** This entry means the parameter is not applicable or has not been set.*

**** This entry means that data is not displayed due to insufficient data privacy clearing.*